Adial Pharmaceuticals 5/14/2024 Earnings Report

Adial Pharmaceuticals EPS Results

• Actual EPS: -$0.68
• Consensus EPS: -$0.51
• Beat/Miss: Missed by -$0.17
• One Year Ago EPS: N/A

Adial Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Adial Pharmaceuticals Announcement Details

• Date: 5/14/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Adial Pharmaceuticals (NASDAQ:ADIL) is a clinical-stage biopharmaceutical company focused on the development of innovative treatments for alcohol dependence and other substance use disorders. The company’s lead product candidate, known as AD04, is a nalmefene-based therapy designed to modulate gene expression pathways implicated in alcohol craving and relapse. Adial leverages proprietary gene expression blockade technology to develop a pipeline of differentiated drug candidates aimed at addressing critical unmet needs in addiction medicine.

Founded in the mid-2000s, Adial Pharmaceuticals has progressed its lead program through preclinical research into early-phase human trials, with the goal of demonstrating safety, tolerability and efficacy in patients suffering from alcohol use disorder. In addition to its work on AD04, the company has initiated exploratory studies in related areas of substance abuse, including cocaine dependence, to broaden its therapeutic reach. Adial’s R&D efforts are supported by collaborations with academic research centers and independent clinical investigators.

Headquartered in North America, Adial maintains operations in the United States and Canada and is pursuing strategic partnerships to facilitate future clinical development and potential commercial access in Europe and Asia. The company’s multidisciplinary team includes experts in neuroscience, regulatory affairs and clinical pharmacology, positioning Adial to navigate the complex regulatory landscape for addiction therapies. Adial also engages with patient advocacy groups to ensure that its clinical programs align with patient needs and standards of care.

Under the leadership of a seasoned management team with deep experience in biotech and pharmaceutical development, Adial Pharmaceuticals continues to advance toward late-stage clinical evaluation. The company’s commitment to scientific rigor and its focus on addressing the societal burden of addiction underscore its mission to deliver novel, effective treatment options for patients worldwide.